{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:36:56Z","timestamp":1792445816651,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejmech.2025.117520","type":"journal-article","created":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T15:27:19Z","timestamp":1742138839000},"page":"117520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Anti-CD64(scFv)-SNAP-Auristatin F: An in vitro proof of concept study for a recombinant antibody conjugate targeting CD64+ acute monocytic leukemia"],"prefix":"10.1016","volume":"290","author":[{"given":"Olusiji Alex","family":"Akinrinmade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel Adebowale","family":"Fajemisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adebukola Kemi","family":"Daramola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Huysamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaolu","family":"Fadeyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Makafui","family":"Dogbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleury A.N.","family":"Biteghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9589-653X","authenticated-orcid":false,"given":"Stefan","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117520_bib1","volume":"11","author":"Juskevicius","year":"2020","journal-title":"Acute Leukemias"},{"key":"10.1016\/j.ejmech.2025.117520_bib2","series-title":"Hematopathology","author":"Naeim","year":"2008"},{"key":"10.1016\/j.ejmech.2025.117520_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.911093","article-title":"Diagnostic challenges in acute monoblastic\/monocytic leukemia in children","volume":"10","author":"Varotto","year":"2022","journal-title":"Front. Pediatric."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117520_bib4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/cyto.b.21219","article-title":"Introduction to the diagnosis and classification of monocytic\u2010lineage leukemias by flow cytometry","volume":"92","author":"Matarraz","year":"2017","journal-title":"Cytometry B Clin. Cytometry"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117520_bib5","first-page":"170","article-title":"Results of the AIEOP AML 2002\/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia","volume":"122","author":"Pession","year":"2013","journal-title":"Blood,J. Am. Soc. Hematol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117520_bib6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/sj.leu.2402446","article-title":"Unique molecular and cellular features of acute myelogenous leukemia stem cells","volume":"16","author":"Jordan","year":"2002","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117520_bib7","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/ajh.26997","article-title":"Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation","volume":"98","author":"Bazinet","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2025.117520_bib8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11899-019-00509-9","article-title":"Chronic myelomonocytic leukemia: 2018 update to prognosis and treatment","volume":"14","author":"Elmariah","year":"2019","journal-title":"Curr. Hematol. Malign. Rep."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117520_bib9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/biomedicines5030056","article-title":"CD64: an attractive immunotherapeutic target for M1-type macrophage mediated chronic inflammatory diseases","volume":"5","author":"Akinrinmade","year":"2017","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117520_bib10","doi-asserted-by":"crossref","first-page":"748","DOI":"10.5858\/2007-131-748-TVOCEI","article-title":"The value of CD64 expression in distinguishing acute myeloid leukemia with monocytic differentiation from other subtypes of acute myeloid leukemia: a flow cytometric analysis of 64 cases","volume":"131","author":"Dunphy","year":"2007","journal-title":"Arch. Pathol. Lab Med."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117520_bib11","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/ijc.28786","article-title":"Targeted ex vivo reduction of CD64\u2010positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B\u2010based cytolytic fusion proteins","volume":"135","author":"Schiffer","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.ejmech.2025.117520_bib12","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1080\/10428194.2020.1775208","article-title":"Fc gamma receptor expression serves as prognostic and diagnostic factor in AML","volume":"61","author":"Heitmann","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117520_bib13","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1365-2559.2012.04175.x","article-title":"The value of immunohistochemistry for CD14, CD123, CD33, myeloperoxidase and CD68R in the diagnosis of acute and chronic myelomonocytic leukaemias","volume":"60","author":"Rollins\u2010Raval","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.ejmech.2025.117520_bib14","first-page":"715","volume":"vol. 18","author":"Walter","year":"2014"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117520_bib15","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.canlet.2013.08.005","article-title":"Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22 (scFv) against leukemic cells","volume":"341","author":"Schiffer","year":"2013","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117520_bib16","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1158\/1535-7163.MCT-08-0554","article-title":"Granzyme B-H22 (scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes","volume":"7","author":"Stahnke","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117520_bib17","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/ijc.25766","article-title":"In vivo efficacy of the recombinant anti\u2010CD64 immunotoxin H22 (scFv)\u2010ETA\u2032 in a human acute myeloid leukemia xenograft tumor model","volume":"129","author":"Tur","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117520_bib18","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00262-015-1763-8","article-title":"Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo","volume":"64","author":"Cremer","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejmech.2025.117520_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.sbi.2016.06.003","article-title":"Design and engineering of deimmunized biotherapeutics","volume":"39","author":"Griswold","year":"2016","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117520_bib20","doi-asserted-by":"crossref","first-page":"897","DOI":"10.18632\/oncotarget.26618","article-title":"Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells","volume":"10","author":"Mungra","year":"2019","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117520_bib21","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody\u2013drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117520_bib22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117520_bib23","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1021\/acsomega.2c06844","article-title":"Click chemistry-generated auristatin F\u2013Linker\u2013Benzylguanine for a SNAP-tag-based recombinant antibody\u2013drug conjugate demonstrating selective cytotoxicity toward EGFR-overexpressing tumor cells","volume":"8","author":"Huysamen","year":"2023","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117520_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-019-0175-x","article-title":"Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia","volume":"7","author":"Yu","year":"2019","journal-title":"Biomark. Res."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117520_bib25","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117520_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00975-2","article-title":"Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia","volume":"13","author":"Cortes","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"30","key":"10.1016\/j.ejmech.2025.117520_bib27","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.2174\/1381612811319300014","article-title":"SNAP-tag technology: a powerful tool for site specific conjugation of therapeutic and imaging agents","volume":"19","author":"Fawzi Hussain","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2025.117520_bib28","series-title":"MAbs","first-page":"1283","article-title":"Recombinant H22 (scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody: a potential strategy to enhance anti-TNF therapy","author":"Hristodorov","year":"2014"},{"key":"10.1016\/j.ejmech.2025.117520_bib29","series-title":"MAbs","first-page":"853","article-title":"Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsies","author":"Hristodorov","year":"2015"},{"key":"10.1016\/j.ejmech.2025.117520_bib30","series-title":"The Condensed Protocols from Molecular Cloning: a Laboratory Manual","author":"Sambrook","year":"2006"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117520_bib31","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1128\/AEM.66.4.1572-1579.2000","article-title":"Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions","volume":"66","author":"Barth","year":"2000","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.ejmech.2025.117520_bib32","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10616-013-9601-3","article-title":"Optimizing the transient transfection process of HEK-293 suspension cells for protein production by nucleotide ratio monitoring","volume":"66","author":"de los Milagros Bassani Molinas","year":"2014","journal-title":"Cytotechnology"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117520_bib33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/71908","article-title":"Resolution of cutaneous inflammation after local elimination of macrophages","volume":"18","author":"Thepen","year":"2000","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117520_bib34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/asheducation-2004.1.98","article-title":"Acute myeloid leukemia","volume":"2004","author":"Stone","year":"2004","journal-title":"Hematology"},{"key":"10.1016\/j.ejmech.2025.117520_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1329529","article-title":"Global, national, and regional burden of acute myeloid leukemia among 60\u201389 years-old individuals: insights from a study covering the period 1990 to 2019","volume":"11","author":"Chen","year":"2024","journal-title":"Front. Public Health"},{"key":"10.1016\/j.ejmech.2025.117520_bib36","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.14116.1","article-title":"Recent advances in the understanding and treatment of acute myeloid leukemia","volume":"7","author":"Watts","year":"2018","journal-title":"F1000Research"},{"issue":"8","key":"10.1016\/j.ejmech.2025.117520_bib37","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.3390\/cancers15082399","article-title":"Optimizing treatment options for newly diagnosed acute myeloid leukemia in older patients with comorbidities","volume":"15","author":"Oshikawa","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117520_bib38","first-page":"53","article-title":"Immunophenotypic characteristics of PB-mobilised CD34+ hematopoietic progenitor cells","volume":"15","author":"Menendez","year":"2001","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.ejmech.2025.117520_bib39","series-title":"Multiparameter Flow Cytometry in the Diagnosis of Hematologic Malignancies","author":"Porwit","year":"2018"},{"issue":"23","key":"10.1016\/j.ejmech.2025.117520_bib40","first-page":"8414","article-title":"Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells","volume":"63","author":"Tur","year":"2003","journal-title":"Cancer Res."},{"issue":"41","key":"10.1016\/j.ejmech.2025.117520_bib41","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.11568","article-title":"CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo","volume":"7","author":"Mladenov","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117520_bib42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2133.2010.09824.x","article-title":"Recombinant, ETA\u2032\u2010based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice","volume":"163","author":"Ribbert","year":"2010","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117520_bib43","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/icb.2016.4","article-title":"Fully human MAP\u2010fusion protein selectively targets and eliminates proliferating CD64+ M1 macrophages","volume":"94","author":"Hristodorov","year":"2016","journal-title":"Immunol. Cell Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117520_bib44","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/CJI.0b013e31816a2d23","article-title":"Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells","volume":"31","author":"Hetzel","year":"2008","journal-title":"J. Immunother."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117520_bib45","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1038\/s41596-019-0214-y","article-title":"One-step site-specific antibody fragment auto-conjugation using SNAP-tag technology","volume":"14","author":"Hussain","year":"2019","journal-title":"Nat. Protoc."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117520_bib46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.canlet.2016.08.003","article-title":"The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F","volume":"381","author":"Woitok","year":"2016","journal-title":"Cancer Lett."},{"issue":"38","key":"10.1016\/j.ejmech.2025.117520_bib47","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.18632\/oncotarget.27730","article-title":"Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies","volume":"11","author":"Biteghe","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.117520_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1203073","article-title":"Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy","volume":"14","author":"Aggarwal","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117520_bib49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117520_bib50","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2741\/2692","article-title":"Macrophage activation and polarization","volume":"13","author":"Martinez","year":"2008","journal-title":"Front. Biosci.-Landmark"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117520_bib51","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2217\/imt-2016-0135","article-title":"Tumor-associated macrophages: implications in cancer immunotherapy","volume":"9","author":"Petty","year":"2017","journal-title":"Immunotherapy"},{"issue":"12","key":"10.1016\/j.ejmech.2025.117520_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243286","article-title":"Using the SNAP-Tag technology to easily measure and demonstrate apoptotic changes in cancer and blood cells with different dyes","volume":"15","author":"Woitok","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.117520_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.618081","article-title":"An antibody-drug conjugate that selectively targets human monocyte progenitors for anti-cancer therapy","volume":"12","author":"Izumi","year":"2021","journal-title":"Front. Immunol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425002855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425002855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:23:16Z","timestamp":1745454196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425002855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":53,"alternative-id":["S0223523425002855"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117520","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-CD64(scFv)-SNAP-Auristatin F: An in vitro proof of concept study for a recombinant antibody conjugate targeting CD64+ acute monocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117520"}}